Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

Bone Marrow Transplantation volume 26, pages 979–983 (2000)Cite this article

Abstract

We studied the effect of complete response (CR) among 126 consecutive patients who underwent stem cell transplantation (SCT) for myeloma. The CR rate with SCT was 33%. Median overall survival (OS) from diagnosis of myeloma was 56 months. OS following SCT was 22 months. Progression-free survival (PFS) was 12 months. OS was not different between patients who achieved CR and those who did not, median survival 25 vs 24 months, P = 0.5. Corresponding median times for PFS were 15 and 11 months, P = 0.2. The plasma cell labeling index (PCLI) was high (⩾1%) in 36% (high risk group) and was associated with poor OS and PFS (P < 0.001). Achieving CR did not influence OS or PFS in either the high or the low risk group. In contrast, OS and PFS were significantly influenced by high PCLI both in patients who achieved CR and those who did not. OS was poor (<30 months) in high risk patients regardless of CR status and in low risk patients who did not achieve CR, compared to low risk patients achieving CR (57 months), making them candidates for novel post-transplant treatment options. Outcome following SCT is dependent more on biological variables such as the PCLI than on CR status. Bone Marrow Transplantation (2000) 26, 979–983.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bataille R, Harousseau JL . Multiple myeloma New Engl J Med 1997 336: 1657–1664

    Article  CAS  Google Scholar 

  2. Greenlee RT, Murray T, Bolden S, Wingo PA . Cancer statistics, 2000 CA Cancer J Clin 2000 50: 7–33

    Article  CAS  Google Scholar 

  3. Myeloma Trialists’ Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 1998 16: 3832–3842

    Article  Google Scholar 

  4. Kovacsovics T, Delaly A . Intensive treatment strategies in myeloma Semin Hematol 1997 34: 49–60

    CAS  PubMed  Google Scholar 

  5. Alexanian R, Dimopoulos M . The treatment of multiplemyeloma New Engl J Med 1994 330: 484–489

    Article  CAS  Google Scholar 

  6. Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479 Cancer 1997 79: 1561–1567

    Article  CAS  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  8. Barlogie B, Jagannath S, Epstein J et al. Biology and therapy of multiple myeloma in 1996 Semin Hematol 1997 34: 67–72

    CAS  PubMed  Google Scholar 

  9. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65

    CAS  PubMed  Google Scholar 

  10. Oivanen TM, Kellokumpu-Lehtinen P, Koivista A-M et al. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia group study Eur J Haematol 1999 62: 109–116

    Article  CAS  Google Scholar 

  11. Kyle RA, Leong T, Oken MM et al. The effect of complete response (CR) on survival in an ECOG phase III trial for multiple myeloma Blood 1998 92: (Suppl. 1) 319a (Abstr. 1310)

    Google Scholar 

  12. Rajkumar SV, Greipp PR . Prognostic factors in multiple myeloma Hematol Oncol Clin North Am 1999 13: 1295–1314

    Article  CAS  Google Scholar 

  13. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 1993 81: 3382–3387

    CAS  PubMed  Google Scholar 

  14. ISCN Mitelman F (ed). An International System for Human Cytogenetics Nomenclature S Karger: 1995 Basel: 1995

  15. Spurbeck JL, Carlson RO, Allen JE, Dewald GW . Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques Cancer Genet Cytogenet 1988 32: 59–66

    Article  CAS  Google Scholar 

  16. Witzig TE, Gonchoroff NJ, Katzmann JA et al. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies J Clin Oncol 1988 6: 1041–1046

    Article  CAS  Google Scholar 

  17. Kaplan E, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  18. Cox DR . Regression models and life tables JR Stat Soc (B) 1972 34: 187–202

    Google Scholar 

  19. Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response J Clin Oncol 1983 1: 710–719

    Article  CAS  Google Scholar 

  20. Tricot G, Sawyer JR, Jagannath S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants J Clin Oncol 1997 15: 2659–2666

    Article  CAS  Google Scholar 

  21. Attal M, Harousseau JL . Standard therapy versus autologous transplantation in multiple myeloma Hematol Oncol Clin North Am 1997 11: 133–146

    Article  CAS  Google Scholar 

  22. Alexanian R, Dimopoulos M, Smith T et al. Limited value of myeloablative therapy for late multiple myeloma Blood 1994 83: 512–516

    CAS  PubMed  Google Scholar 

  23. Fermand JP, Ravaud P, Chevret S et al. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): results of a prospective randomized trial Blood 1996 88: (Suppl. 1) 685a (Abstr. 2730)

    Google Scholar 

Download references

Acknowledgements

Drs Rajkumar and Fonseca are Leukemia and Lymphoma Society Translational Research Awardees. This work was also supported in part by CA 62242 and CA 85818 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Dr Rajkumar is also supported by the Judith and George Goldman Foundation Fighting Catastrophic Diseases.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    SV Rajkumar, R Fonseca, A Dispenzieri, MQ Lacy, TE Witzig, JA Lust, RA Kyle, MR Litzow, PR Greipp & MA Gertz

  2. Division of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    D Larson & TM Therneau

Authors
  1. SV Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. MQ Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. TE Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JA Lust
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. TM Therneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. RA Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. MR Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. PR Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. MA Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajkumar, S., Fonseca, R., Dispenzieri, A. et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 26, 979–983 (2000). https://doi.org/10.1038/sj.bmt.1702640

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702640

Keywords

This article is cited by

Search

Advanced search

Quick links